mmv367

Small moleculeexperimental

Clinical trial activity

2 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 29, 2022 (NCT05507970)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05979207Phase 1Aug 1, 2023GlaxoSmithKline, ICON, Medicines for Malaria Venture, Southern Star Research Pty Ltd., Sunshine Coast University, Australia, Swiss BioQuant A.G., Switzerland, University of Queensland
NCT05507970Phase 1Jul 29, 2022Banook Group, GlaxoSmithKline, Medicines for Malaria Venture, Quotient, Swiss BioQuant A.G., Switzerland, The Doctors Laboratory Ltd
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit2012022
Medicines for Malaria VentureAcademic/Hospital2212022
Swiss BioQuant A.G., SwitzerlandFor profit2012022
Banook GroupFor profit1012022
ICONFor profit1012023
QuotientFor profit1012022
Southern Star Research Pty Ltd.For profit1012023
Sunshine Coast University, AustraliaAcademic/Hospital1012023
The Doctors Laboratory LtdAcademic/Hospital1012022
University of QueenslandAcademic/Hospital1012023
10 organizations
Page 1 / 1